KOSUNI KOREA
Korean News in English
Business

D&D Pharmatech Stock Outlook and Market Prospects

Published October 11, 2026 · 2 views
D&D Pharmatech Stock Outlook and Market Prospects

디앤디파마텍 주가 예측과 시장 전망

Background of D&D Pharmatech's Stock Surge

D&D Pharmatech has seen its stock price rise sharply due to development of an anti-obesity medication. Key drivers include technology transfer and clinical trial results, with the 2026 May-June tissue biopsy results and the DD01 technology transfer agreement being significant upcoming events.

IPO Process and Market Reaction

D&D Pharmatech is a biotech company holding development technology for oral anti-obesity drugs. Its IPO saw strong demand with a general subscription ratio of 1,544:1 and collected 700 billion won in margin deposits, making it a successful listing. After listing, the stock faced overvaluation concerns alongside rising expectations about technology exports.

On April 23, 2024, during general subscriptions, D&D Pharmatech recorded a subscription ratio of 1,544:1 and raised 7 trillion won in margin deposits. The company officially listed on April 30 under the lead of Korea Investment Securities. Even after its successful IPO, market expectations about technology transfers increased, leading to greater stock volatility.

Technology Transfer and Clinical Trial Results

The most important catalyst for D&D Pharmatech is the tissue biopsy results expected in May-June 2026, with technology transfer potentially occurring before or after this event. The DD01 technology transfer agreement is imminent, with further strategies anticipated following the deal.

At a company visit on December 15, 2025, D&D Pharmatech explained its tissue biopsy results and technology transfer plans. On January 8, 2026, news broke about the impending DD01 technology transfer agreement. These reports have drawn market attention, increasing stock volatility and investor interest.

D&D Pharmatech is advancing MASH new drug technology transfer and partner negotiations with high expectations. CEO Lee Seul announced plans to push for MASH new drug technology transfers in the first half of 2026. The MASH market is projected at 1 trillion won, while the anti-obesity drug market is expected to reach 100 trillion won.

In the first half of 2026, D&D Pharmatech plans to advance MASH new drug technology transfer and enter due diligence stages. The DD01 technology transfer agreement is expected to be completed by April 2026, potentially leading to a re-evaluation of the company's enterprise value.

Pfizer Clinical Collaboration and Stock Volatility

D&D Pharmatech experienced a turning point in its stock volatility due to clinical collaboration with Pfizer. On January 19, 2026, news about the collaboration caused a significant stock surge, followed by ongoing efforts to issue convertible bonds (CB) ahead of data releases.

Kiwoom Securities noted increased clinical credibility and expanded expectations regarding technology transfers. On April 8, 2026, reports emerged about the company's CB initiative ahead of data releases scheduled for April 9. On the same day, there were also reports about stock compensation related to the obesity treatment drug.

On April 30, 2026, a report analyzed D&D Pharmatech's declining stock price. This decline appears linked to uncertainty regarding data release expectations following the Pfizer collaboration announcement.

As of April 2026, D&D Pharmatech's stock has been trending downward, with investors considering repurchase strategies during post-listing declines. This reflects ongoing concerns about overvaluation from its IPO, which saw a high subscription ratio and significant margin deposits.

디앤디파마텍 주가 예측과 시장 전망

Status of Technology Transfer Agreement

The DD01 technology transfer agreement is expected to be completed by April 2026. Following the deal, analysts anticipate further strategic moves, with some suggesting potential re-evaluation of the company's enterprise value next year.

Obesity Treatment Market Outlook

D&D Pharmatech is preparing to enter the obesity treatment market through its development of oral anti-obesity drugs. High expectations exist for MASH new drug technology transfer and partner negotiations. The projected 10 trillion won MASH market and 100 trillion won anti-obesity drug market are expected to support D&D Pharmatech's growth.

Oralink application has confirmed improved absorption rates of large cyclic peptides, providing a key technical foundation for oral anti-obesity drug development. D&D Pharmatech is leveraging this technology to enhance its competitive position in the market.

Investor Reaction and Stock Volatility

After listing, D&D Pharmatech's stock experienced increased volatility alongside overvaluation concerns. The IPO general subscription ratio of 1,544:1 demonstrated strong investor interest, which also influenced post-listing performance.

While the market noted overvaluation due to technology export expectations, the stock has been trending downward as of April 2026. This decline appears linked to uncertainty about data release prospects following the Pfizer collaboration announcement.

Future Expectations

D&D Pharmatech expects to meet market expectations through tissue biopsy results in May-June 2026 and completion of the DD01 technology transfer agreement. High expectations for MASH new drug technology transfer and partner negotiations are also driving increased interest in entering the obesity treatment market.

Analysts suggest potential re-evaluation of enterprise value next year, which could lead to ongoing stock volatility. Investors may consider repurchase strategies during post-listing declines, making the completion of technology transfer agreements and clinical results announcements critical moving forward.

Key Information to Verify

Tissue biopsy results for D&D Pharmatech are expected in May-June 2026, with the DD01 technology transfer agreement anticipated by April 2026. The MASH market is projected at 10 trillion won, while the anti-obesity drug market is estimated at 100 trillion won.

Following news of clinical collaboration with Pfizer, the company has been pursuing convertible bond (CB) initiatives ahead of data releases. On April 30, 2026, a report analyzed the stock decline, reflecting heightened market expectations regarding technology transfer completion and clinical results announcements.

Frequently Asked Questions

Q: What is D&D Pharmatech's main business focus? A: D&D Pharmatech holds development technology for oral anti-obesity drugs and has experienced stock volatility due to clinical collaboration with Pfizer. Tissue biopsy results are expected in May-June 2026.

Q: What was the IPO subscription ratio and margin deposits? A: The IPO general subscription had a ratio of 1,544:1, collecting 7 trillion won in margin deposits. After listing, stock faced overvaluation concerns but rose due to technology export expectations.

Q: When is MASH new drug technology transfer planned? A: MASH new drug technology transfer efforts are scheduled for the first half of 2026, with a projected market size of 10 trillion won. The anti-obesity drug market is estimated at 100 trillion won.

Frequently Asked Questions

Q: How does D&D Pharmatech plan to maintain stock volatility? A: The company's stock volatility stems from obesity treatment development and technology transfer efforts. Key upcoming events include tissue biopsy results in May-June 2026 and completion of the DD01 technology transfer agreement, which are expected to draw market attention.

Q: What is the projected market size for MASH drugs? A: The MASH drug market is projected at 10 trillion won, while the anti-obesity drug market is estimated at 100 trillion won. These figures support D&D Pharmatech's growth strategy as it prepares to enter these markets.

Read More Related Articles

You can view similar articles on this topic in one place.

View Related Articles

FAQ

What is D&D Pharmatech's main business focus?

D&D Pharmatech holds development technology for oral anti-obesity drugs and has experienced stock volatility due to clinical collaboration with Pfizer. Tissue biopsy results are expected in May-June 2026.

What was the IPO subscription ratio and margin deposits?

The IPO general subscription had a ratio of 1,544:1, collecting 7 trillion won in margin deposits. After listing, stock faced overvaluation concerns but rose due to technology export expectations.

When is MASH new drug technology transfer planned?

MASH new drug technology transfer efforts are scheduled for the first half of 2026, with a projected market size of 10 trillion won. The anti-obesity drug market is estimated at 100 trillion won.

Korean Source

This article is an English localization of a Korean-language report from BlogScore. Original: 디앤디파마텍 주가 예측과 시장 전망